Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lisata Therapeutics Named 'Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough Awards

Lisata Therapeutics receives the ‘Specialized BioTherapeutics Company of the Year’ award for innovative cancer therapies and clinical advancements.Quiver AI SummaryLisata Therapeutics, Inc., a clinical-stage...

LSTA : 2.84 (-2.94%)
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

LSTA : 2.84 (-2.94%)
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

LSTA : 2.84 (-2.94%)
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a...

FOLD : 9.50 (-0.94%)
ESPR : 2.47 (+2.49%)
CRSP : 46.29 (-2.05%)
LSTA : 2.84 (-2.94%)
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

LSTA : 2.84 (-2.94%)
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

LSTA : 2.84 (-2.94%)
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

LSTA : 2.84 (-2.94%)
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

LSTA : 2.84 (-2.94%)
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

LSTA : 2.84 (-2.94%)
Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

/PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the...

LSTA : 2.84 (-2.94%)

Barchart Exclusives

Recent Corn Rally Artificially Propped Up – What’s Next?
Corn prices appeared to have finally found a bottom from the summer sell-off. Speculators were short the market in record numbers until late August, when they began buying back contracts, convincing some that the harvest seasonal low may be in. Then, exports increased in the last few weeks, and prices rallied more. While the bearish fundamentals of 1.9 billion carry-out and the massive amount of unpriced corn still linger, there isn’t much hope for a significant price rally yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar